Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.

Abstract

In a prospective, randomized, double-blind trial the combination betamethasone-dixyrazine was compared with high-dose metoclopramide as antiemetic treatment during combination chemotherapy (melphalan-doxorubicin and cisplatin) of ovarian carcinoma. Of 40 evaluable patients, 15 (38%) had previous experience with chemotherapy. Efficacy and side effects were recorded on patient and nurse questionnaires using the visual analog scale. Nausea and vomiting were prevented in 55% of the patients treated with melphalan-doxorubicin (Day 1) and in 36% of the patients treated with cisplatin (Day 2). Betamethasone-dixyrazine was superior to high-dose metoclopramide and prevented nausea in 76% compared to 32% during melphalan-doxorubicin therapy. Akathisia was noted in 21% and acute dystonic reactions in 2.6% during metoclopramide treatment but not in any case during betamethasone-dixyrazine therapy.

• Authors: B Sorbe, C Hallén
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 34 Issue 2 Pg. 141-4 (Aug 1989) ISSN: 0090-8258 [Print] United States
• PMID: 2568970 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antipsychotic Agents
• Phenothiazines
• dixyrazine
• Doxorubicin
• Betamethasone
• Metoclopramide
• Cisplatin
• Melphalan

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Antipsychotic Agents (therapeutic use)
• Betamethasone (therapeutic use)
• Cisplatin (administration & dosage)
• Clinical Trials as Topic
• Doxorubicin (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Melphalan (administration & dosage)
• Metoclopramide (therapeutic use)
• Nausea (chemically induced, drug therapy)
• Ovarian Neoplasms (drug therapy)
• Phenothiazines (therapeutic use)
• Prospective Studies
• Random Allocation